What is Tisotumab vedotin-tftv?

Vetin-Tisotumab vedotin-tftv is a targeted therapy called an antibody-drug conjugate. It is made by chemically linking a monoclonal antibody to an anti-cancer drug. Monoclonal antibodies bind to proteins on the surface of some cancer cells. Related drugs enter these cancer cells and kill them. Vitin-Tisotuzumab also stimulates the immune system to kill cancer cells.

Vitin-Tisotuzumab is approved for the treatment of recurrent or metastatic cervical cancer. It is mainly used in women whose cancer has progressed during or after chemotherapy. Vitin-Tisotuzumab passed the accelerated approval process of the U.S. Food and Drug Administration (FDA). As a condition of approval, confirmatory trials must demonstrate clinical benefit in these patients. Vitin-Tisotuzumab is also being used to treat other types of cancer. The recommended dose of Vitin-Tisotuzumab is 2 mg/kg (for patients ≥100kg, the maximum dose is 200 mg), as a 30-minute intravenous infusion every 3 weeks until disease progression or unacceptable toxicity occurs. The most common adverse reactions are fatigue, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival adverse reactions, bleeding, dry eye, diarrhea and rash.

Vitin-TisotumabThe original drug has not yet been marketed in China, so it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.